NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer 2016. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (date last accessed 1 February 2016).
Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56: 823–827.
Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI et al. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int 2004; 94: 42–46.
Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS et al. Gleason score and lethal prostate cancer: does 3+4=4+3? J Clin Oncol 2009; 27: 3459–3464.
Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 2013; 64: 895–902.
Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006; 175: 547–551.
Spratt DE, Zumsteg Z, Ghadjar P, Pangasa M, Pei X, Fine SW et al. Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis. Int J Radiat Oncol Biol Phys 2013; 85: 1254–1261.
Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 2005; 23: 2911–2917.
Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C et al. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer 2013; 119: 3287–3294.
Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schaeffer EM et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 2010; 76: 715–721.
Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011; 81: e351–e360.
Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J et al. Patients with biopsy Gleason 9 and 10 prostate cancer have significantly worse outcomes compared to patients with Gleason 8 disease. J Urol 2015; 194: 91–97.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013; 111: 753–760.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C et al. A Contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2015; 69: 428–435.
Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965–974.
Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 1996; 143: 1059–1068.
Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.
Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273–279.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869–875.
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr., Yossepowitch O, Vickers AJ et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300–4305.
D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008; 26: 2979–2983.
Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035–2041.
Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 6992–6998.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.
Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Gleason score 3+5 or 5+3 versus 4+4 prostate cancer: the risk of death. Eur Urol 2015; 69: 976–979.
Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC et al. Gleason score 5+3=8 prostate cancer: much more like Gleason score 9? BJU Int, e-pub ahead of print 24 July 2015; doi: 10.1111/bju.13239.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et alThe 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244–252.
Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972–3978.
Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res 2015; 75: 4688–4696.